Results 111 to 120 of about 2,487 (198)

Nirsevimab and other strategies for the prevention of RSV infection

Anales de Pediatría (English Edition), 2023
Antonio, Iofrío de Arce, Francisco José, Álvarez García   +1 more
openaire   +2 more sources

Efficacy and safety of a single dose of nirsevimab against respiratory syncytial virus infection in infants: a meta-analysis and time-to-event analysis

Italian Journal of Pediatrics
Respiratory syncytial virus (RSV) is one of the causes of lower respiratory tract infections (LRTIs) and related hospitalizations in neonates and infants.
Mohamed Saad Sayed, Mena Ayman Elgendy, Nada Gamil, Hossam Hassan Abdullah, Alaa Alhwary, Rahma Abdulfattah Ibrahim, Sama Hesham Samir, Nada S. Jibril, Hebatullah Abdulazeem, Mohammed Alsabri   +9 more
doaj   +1 more source

Optimal implementation of an Ontario nirsevimab program for respiratory syncytial virus (RSV) prophylaxis: Recommendations from a provincial RSV expert panel

Human Vaccines & Immunotherapeutics
In June 2024, a group of 12 experts in the respiratory syncytial virus (RSV) field representing a cross-section of healthcare provider types who treat and care for pregnant individuals and infants, assembled to discuss the implementation of a broad ...
Bosco Paes, Vivien Brown, Erin Courtney, Erin Fleischer, Fiona Guy, Eddy Lau, Allan Mills, Julie Toole, Meagan Bardan, Cynthia Wong, Gary Lam, Graeme N. Smith   +11 more
doaj   +1 more source

Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged <8 Months — United States, April 2024

MMWR. Morbidity and mortality weekly report
Respiratory syncytial virus (RSV) is the most common cause of hospitalization among U.S. infants. CDC recommends RSV vaccination for pregnant persons or administration of RSV antibody (nirsevimab) to infants aged
H. Razzaghi, Emma Garacci, Katherine E. Kahn, Megan C. Lindley, Jefferson M. Jones, Shannon Stokley, Kayla Calhoun, Carla L. Black   +7 more
semanticscholar   +1 more source

Nirsevimab: a promising therapy for RSV

The Lancet Microbe, 2022
openaire   +1 more source

Uptake and predictors of newborn respiratory syncytial virus (RSV) immunisation with nirsevimab in Ireland's national pilot programme: a cross-sectional study. [PDF]

BMJ Open
Masukume G, McMorrow A, Dawood I, Rafdhy K, O'Brien F, Desmond C, O'Connell D, Murphy B, Ronan E, Purtill H, Philip RK.   +10 more
europepmc   +1 more source

Virus Detection and Hospitalization Rate in Infants With Bronchiolitis After Nirsevimab Introduction: A Retrospective Comparative Two-Season Study. [PDF]

Pediatr Pulmonol
La Regina DP, Spatuzzo M, Bonci E, Nenna R, Petrarca L, Conti MG, Mancino E, Pierangeli A, Antonelli G, Midulla F.   +9 more
europepmc   +1 more source

Impact of a national nirsevimab programme on critical care transport of babies with bronchiolitis: a retrospective observational study. [PDF]

Arch Dis Child
Moore T, Afridi A, Aminudin NH, Gibbons C, Grant O, Fucikova H, Moore CM.   +6 more
europepmc   +1 more source

Evaluating respiratory syncytial virus immunization strategies for infants in Canada: A cost-utility analysis. [PDF]

PLoS One
Gebretekle GB, Lan M, Xi M, Ximenes R, Buchan SA, Abrams EM, Andrew MK, Brousseau N, Killikelly A, Money D, Papenburg J, Rafferty E, Robinson JL, Siu W, Tunis M, Tuite AR.   +15 more
europepmc   +1 more source

Efficacy and effectiveness of long-acting monoclonal antibodies and vaccines against RSV: a systematic review and meta-analysis of studies from 2018 to 2025. [PDF]

EClinicalMedicine
Du J, Li S, Hung IFN, Wu JT, Leung K.
europepmc   +1 more source